Published date: 3 January 2023

This notice was replaced on 3 January 2023

This notice does not contain the most up-to-date information about this procurement. The most recent notice is:

Opportunity (published 3 January 2023, last edited 3 January 2023)

Closed opportunity - This means that the contract is currently closed. The buying department may be considering suppliers that have already applied, or no suitable offers were made.


Contract summary

Industry

  • Research laboratory services - 73111000

Location of contract

WC1N 3JH

Value of contract

£150,000

Procurement reference

CF-1253000D0O000000rwimUAA

Published date

3 January 2023

Closing date

20 January 2023

Closing time

12pm

Contract start date

1 March 2023

Contract end date

31 December 2023

Contract type

Not applicable

Procedure type

Open procedure (below threshold)

Any interested supplier may submit a tender in response to an opportunity notice.

This procedure can be used for procurements below the relevant contract value threshold.

Contract is suitable for SMEs?

Yes

Contract is suitable for VCSEs?

Yes

Description

The NHS Genomic Medicine Service infrastructure, including the seven Genomic Laboratory Hubs (GLHs), enable the full repertoire of genomics testing for cancer patients in the NHS in England as outlined in the National Genomic Test Directory (Test Directory). Most of the somatic cancer testing in the Test Directory is based on testing the genetic make-up of an individual's tumour. This requires a tumour sample to be taken and then sent to the GLHs for testing.
Increasingly it is becoming possible to use blood samples to test the circulating free DNA (cfDNA) for the presence of disease-causing mutations in circulating tumour DNA (ctDNA), also known as liquid biopsy testing. ctDNA based testing has now been validated, pan-cancer, in a number of different trials including I-SPY2, FLAUAS, AURA3, SCRUM-Japan, GOZILA, GRECO, MYSTIC, PEGASUS, COBRA, SOLAR1 and plasmaMATCH. ctDNA testing for EGFR gene mutations is already included on the Test Directory for lung cancer patients.
To build the evidence base for the further roll out of ctDNA testing in the NHS, NHS England convened a group of experts to scope a project to explore ctDNA starting with suspected stage 3/4 non-small cell lung cancer patients.
ctDNA samples will be taken from at least 700 patients with suspected thoracic malignancy without a confirmed histological diagnosis of stage 3/4 non-small cell lung cancer for direct gene panel analysis for those genes already approved on the Test Directory.
ctDNA samples taken prior to the start of this project for patients with non-small cell lung cancer taken at the same time as tissue biopsy or after histological verification in parallel to tissue molecular analyses will also be included in this health economics evaluation. Numbers to be confirmed.

About the buyer

Contact name

Mart Somerville

Address

200 Great Dover Street
London
SE1 4BY
GB

Email

mark.somerville@gstt.nhs.uk